EGFR expression in advanced head and neck cutaneous squamous cell carcinoma

Head and Neck

Volumn 34, Issue 5, 2012, Pages 681-686

  Sweeny, Larissa ^a   Dean, Nichole R ^a   Magnuson, J Scott ^a   Carroll, William R ^a   Helman, Emily E ^a   Hyde, Stephen O ^a   Desmond, Renee L ^b   Rosenthal, Eben L ^a  

^a Kentucky   (United States)

^b University of Alabama at Birmingham   (United States)

Author keywords

cutaneous squamous cell carcinoma; epidermal growth factor receptor; head and neck; nonmelanoma skin cancer; survival

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER STAGING; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GENE OVEREXPRESSION; HEAD AND NECK CARCINOMA; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGIONAL METASTASIS; RETROSPECTIVE STUDY; SKIN CARCINOMA; SQUAMOUS CELL CARCINOMA; SURVIVAL TIME;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, SQUAMOUS CELL; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; RECEPTOR, EPIDERMAL GROWTH FACTOR; RETROSPECTIVE STUDIES; SKIN NEOPLASMS;

EID: 84859736005     PISSN: 10433074     EISSN: 10970347     Source Type: Journal    
DOI: 10.1002/hed.21802     Document Type: Article

References (33)

1. Alam M, Ratner D,. Cutaneous squamous-cell carcinoma. N Engl J Med 2001; 344: 975-983.
2. Greenlee RT, Hill-Harmon MB, Murray T, Thun M,. Cancer statistics, 2001. CA Cancer J Clin 2001; 51: 15-36.
3. Joseph AK, Mark TL, Mueller C,. The period prevalence and costs of treating nonmelanoma skin cancers in patients over 65 years of age covered by Medicare. Dermatol Surg 2001; 27: 955-959.
4. Hynes NE, Lane HA,. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer 2005; 5: 341-354.
5. Rubin Grandis J, Melhem MF, Gooding WE, et al. Levels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival. J Natl Cancer Inst 1998; 90: 824-832.
6. Kalyankrishna S, Grandis JR,. Epidermal growth factor receptor biology in head and neck cancer. J Clin Oncol 2006; 24: 2666-2672.
7. AJCC cancer staging manual. 7th ed. New York: Springer-Verlag; 2009. p xiv.
8. Atkins D, Reiffen KA, Tegtmeier CL, Winther H, Bonato MS, Storkel S,. Immunohistochemical detection of EGFR in paraffin-embedded tumor tissues: variation in staining intensity due to choice of fixative and storage time of tissue sections. J Histochem Cytochem 2004; 52: 893-901.
9. Herbst RS, Langer CJ,. Epidermal growth factor receptors as a target for cancer treatment: the emerging role of IMC-C225 in the treatment of lung and head and neck cancers. Semin Oncol 2002; 29 (Suppl 4): 27-36.
10. Rubin Grandis J, Tweardy DJ, Melhem MF,. Asynchronous modulation of transforming growth factor alpha and epidermal growth factor receptor protein expression in progression of premalignant lesions to head and neck squamous cell carcinoma. Clin Cancer Res 1998; 4: 13-20.
11. Ang KK, Berkey BA, Tu X, et al. Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. Cancer Res 2002; 62: 7350-7356.
12. Eriksen JG, Steiniche T, Askaa J, Alsner J, Overgaard J,. The prognostic value of epidermal growth factor receptor is related to tumor differentiation and the overall treatment time of radiotherapy in squamous cell carcinomas of the head and neck. Int J Radiat Oncol Biol Phys 2004; 58: 561-566.
13. Temam S, Kawaguchi H, El-Naggar AK, et al. Epidermal growth factor receptor copy number alterations correlate with poor clinical outcome in patients with head and neck squamous cancer. J Clin Oncol 2007; 25: 2164-2170.
14. Gold KA, Lee HY, Kim ES,. Targeted therapies in squamous cell carcinoma of the head and neck. Cancer 2009; 115: 922-935.
15. Smith BD, Haffty BG,. Molecular markers as prognostic factors for local recurrence and radioresistance in head and neck squamous cell carcinoma. Radiat Oncol Invest 1999; 7: 125-144.
16. Quon H, Liu FF, Cummings BJ,. Potential molecular prognostic markers in head and neck squamous cell carcinomas. Head Neck 2001; 23: 147-159.
17. Herbst RS,. Review of epidermal growth factor receptor biology. Int J Radiat Oncol Biol Phys 2004; 59 (Suppl 2): 21-26.
18. Bauknecht T, Gross G, Hagedorn M,. Epidermal growth factor receptors in different skin tumors. Dermatologica 1985; 171: 16-20.
19. Lavrijsen AP, Tieben LM, Ponec M, van der Schroeff JG, van Muijen GN,. Expression of EGF receptor, involucrin, and cytokeratins in basal cell carcinomas and squamous cell carcinomas of the skin. Arch Dermatol Res 1989; 281: 83-88.
20. Shimizu T, Izumi H, Oga A, et al. Epidermal growth factor receptor overexpression and genetic aberrations in metastatic squamous-cell carcinoma of the skin. Dermatology 2001; 202: 203-206.
21. Maubec E, Duvillard P, Velasco V, Crickx B, Avril MF,. Immunohistochemical analysis of EGFR and HER-2 in patients with metastatic squamous cell carcinoma of the skin. Anticancer Res 2005; 25: 1205-1210.
22. Ch'ng S, Low I, Ng D, et al. Epidermal growth factor receptor: a novel biomarker for aggressive head and neck cutaneous squamous cell carcinoma. Hum Pathol 2008; 39: 344-349.
23. Fischer C, Zlobec I, Stockli E, et al. Is immunohistochemical epidermal growth factor receptor expression overestimated as a prognostic factor in head-neck squamous cell carcinoma? A retrospective analysis based on a tissue microarray of 365 carcinomas. Hum Pathol 2008; 39: 1527-1534.
24. van Diest PJ, van Dam P, Henzen-Logmans SC, et al. A scoring system for immunohistochemical staining: consensus report of the task force for basic research of the EORTC-GCCG. European Organization for Research and Treatment of Cancer-Gynaecological Cancer Cooperative Group. J Clin Pathol 1997; 50: 801-804.
25. Lee KP, Boyd EA, Holroyd-Leduc JM, Bacchetti P, Bero LA,. Predictors of publication: characteristics of submitted manuscripts associated with acceptance at major biomedical journals. Med J Aust 2006; 184: 621-626.
26. Cohen EE, Davis DW, Karrison TG, et al. Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: a phase I/II study. Lancet Oncol 2009; 10: 247-257.
27. Stewart JS, Cohen EE, Licitra L, et al. Phase III study of gefitinib compared with intravenous methotrexate for recurrent squamous cell carcinoma of the head and neck. J Clin Oncol 2009; 27: 1864-1871.
28. Cohen EE, Rosen F, Stadler WM, et al. Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol 2003; 21: 1980-1987.
29. Soulieres D, Senzer NN, Vokes EE, Hidalgo M, Agarwala SS, Siu LL,. Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. J Clin Oncol 2004; 22: 77-85.
30. Numico G, Russi EG, Colantonio I, et al. EGFR status and prognosis of patients with locally advanced head and neck cancer treated with chemoradiotherapy. Anticancer Res 2010; 30: 671-676.
31. Gupta AK, McKenna WG, Weber CN, et al. Local recurrence in head and neck cancer: relationship to radiation resistance and signal transduction. Clin Cancer Res 2002; 8: 885-892.
32. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM,. Reporting recommendations for tumor marker prognostic studies (REMARK). J Natl Cancer Inst 2005; 97: 1180-1184.
33. Givi B, Andersen PE, Diggs BS, Wax MK, Gross ND,. Outcome of patients treated surgically for lymph node metastases from cutaneous squamous cell carcinoma of the head and neck. Head Neck. 2011 Jan 31. doi: 10.1002/hed21574 [Epub ahead of print].